T1	SectionAnnotate 0 4	HPI:
T2	SectionAnnotate 4585 4606	Past Medical History:
T3	SectionAnnotate 4667 4689	Past Surgical History:
T4	SectionSkip 4824 6269	Current Outpatient Prescriptions:     cholecalciferol, vitamin D3, (VITAMIN D3 ORAL), Take by mouth., Disp: , Rfl:     multivitamin tablet, Take 1 tablet by mouth Daily., Disp: , Rfl:     SYNTHROID 112 mcg tablet, Take 112 mcg by mouth Daily. , Disp: , Rfl:     acetaminophen (TYLENOL) 500 mg tablet, Take 2 tablets (1,000 mg total) by mouth every 8 (eight) hours as needed for Pain. (Patient not taking: Reported on 11/06/2017), Disp: 100 tablet, Rfl: 1    docusate sodium (COLACE) 100 mg capsule, Take 1 capsule (100 mg total) by mouth Twice a day. While taking oxycodone to prevent constipation (Patient not taking: Reported on 11/06/2017), Disp: 30 capsule, Rfl: 1    HYDROcodone-acetaminophen (NORCO) 5-325 mg tablet, Take 1 tablet by mouth every 4 (four) hours as needed for Pain. (Patient not taking: Reported on 11/06/2017), Disp: 26 tablet, Rfl: 0    ibuprofen (ADVIL,MOTRIN) 600 mg tablet, Take 1 tablet (600 mg total) by mouth every 8 (eight) hours as needed for Pain. (Patient not taking: Reported on 
 11/06/2017), Disp: 60 tablet, Rfl: 1    LORazepam (ATIVAN) 0.5 mg tablet, Take 0.5 mg by mouth every 6 (six) hours as needed for Anxiety., Disp: , Rfl:     oxyCODONE (ROXICODONE) 5 mg tablet, Take 1-2 tablets (5-10 mg total) by mouth every 6 (six) hours as needed for Pain. (Patient not taking: Reported on 11/06/2017), Disp: 20 tablet, Rfl: 0  No current facility-administered medications for this visit.     Gynecologic
T5	SectionAnnotate 6399 6413	Social History
T6	SectionAnnotate 6418 6442	Social History Narrative
T7	SectionAnnotate 6663 6677	Family History
T8	SectionAnnotate 6750 6767	Review of Systems
T9	SectionSkip 7029 8583	Physical Examination: General appearance - alert, well appearing, and in no distress  BP 99/68  | Pulse 65  | Temp 36.1 C (96.9 F) (Oral)  | Resp 18  | Ht 157.5 cm (5' 2")  | Wt 77 kg (169 lb 11.2 oz)  | LMP 10/13/2017  | SpO2 96%  | BMI 31.04 kg/m   Mental status - alert, oriented to person, place, and time  Eyes - pupils equal and reactive, extraocular eye movements intact  Mouth - mucous membranes moist, pharynx normal without lesions  Neck - supple, no significant adenopathy  Lymphatics - no palpable lymphadenopathy, no hepatosplenomegaly  Chest - clear to auscultation, no wheezes, symmetric air entry  Heart - normal rate, regular rhythm, no murmurs  Abdomen - soft, nontender, nondistended, no masses or organomegaly  Breasts - breast exam not done, 
 no axillary LN palpable.   Back exam - full range of motion, no tenderness, palpable spasm or pain on motion  Neurological - alert, oriented, normal speech, no focal findings or movement disorder noted  Musculoskeletal - no joint tenderness, deformity or swelling  Extremities - peripheral pulses normal, no pedal edema  Skin - no rashes, no suspicious skin lesions noted    Labs reviewed and discussed with patient:  Results for orders placed or performed during the hospital encounter of 10/31/17   POCT glucose, Fingerstick   Result Value Ref Range    Glucose, meter download 93 70 - 199 mg/dL       Imaging results reviewed and discussed with patient:  Mr Brain With And Without Contrast    Result Date: 11/03/2017  MR BRAIN WITH AND WITHOUT CONTRAST : *****/*****/***** *****:***** PM
T10	SectionSkip 8826 9794	FINDINGS: Homogenously-enhancing, partially calcified 5 mm right parafalcine extra-axial mass with dural attachment. Anteriorly, a dural calcification of the anterior falx does not demonstrate abnormal enhancement. Normal brain parenchyma and signal intensity. No abnormal enhancement of the brain. Heterogenous skull base and calvarial bone marrow without evidence of focal lesion. No abnormal reduced diffusion within the calvarium. Normal flow-related signal voids. Left maxillary sinus mucus retention cyst.     5 mm right parafalcine dural-based mass is most likely a meningioma, although dural-based metastasis remains an unlikely possibility; follow-up imaging in 6 months may be helpful.      Petct Limited Whole Body Vertex To Mid Thigh    Result Date: 10/31/2017  PET/CT Whole Body (vertex to thighs)    *****/*****/***** *****:***** PM COMPARISON (including at least the prior year or since last change in therapy):   None REASON FOR THE 
 STUDY:   Staging.
T13	SectionSkip 18311 18689	Findings: There is an enlarged lymph node measuring 7 x 7 x 7 mm in the right axilla, at approximately 10 o'clock, 14 cm from nipple.     Right breast: Suspicious (BI-RADS 4). Recommendations: Ultrasound guided FNA of the enlarged right axillary lymph node was performed immediately following this examination. Please see separate procedure report. Radiologist ***** *****, M.D.
T14	SectionSkip 18694 19448	Pathology results reviewed and discussed with the patient:  CYTOPATHOLOGY REPORT    Patient Name: *****, *****  *****. Rec.#: *****  DOB: 12/02/1980 (Age: 36)  Sex: Female  Accession #: *****-*****  Visit #: *****  Service Date: 10/28/2017  Received: 10/28/2017  Location: *****  Client: *****   Physician(s): ***** *****. ***** ((*****) *****-*****)  ***** *****. ***** ((*****) *****-*****)    Source of Specimen:  Rigth axilla lymph node, fine needle aspiration biopsy      FINAL CYTOLOGIC DIAGNOSIS:  A: Lymph node, right axilla, fine needle aspiration biopsy: Metastatic  carcinoma; see comment.     SURGICAL *****/*****/*****  ***** Health Affiliates and Community Connect Practices  Result Narrative   CASE: *****-*****-*****  PATIENT: ***** *****
T15	SectionAnnotate 20036 20056	Assessment and Plan:
T16	PROBLEM 43 89	a recently diagnosed hormone receptor positive
T17	PROBLEM 90 137	HER2 negative node positive right breast cancer
T18	TREATMENT 170 177	surgery
T19	TREATMENT 213 230	treatment options
T20	TEST 235 258	recent imaging findings
T21	TEST 279 290	a mammogram
T22	PROBLEM 347 402	an 1.8 cm irregular hyperdense mass in the right breast
T23	PROBLEM 442 467	malignancy in left breast
T24	TEST 469 471	US
T25	PROBLEM 481 515	a 1.7 cm irregular hypoechoic mass
T26	PROBLEM 549 574	2 prominent axillary LNs.
T27	TEST 575 610	US guided core biopsy of the breast
T28	PROBLEM 632 657	invasive ductal carcinoma
T29	TEST 673 675	PR
T30	TEST 687 691	HER2
T31	TEST 695 698	IHC
T32	TEST 717 721	Ki67
T33	TEST 731 749	Histologic grading
T34	TEST 842 858	An MRI of breast
T35	PROBLEM 901 948	a 2.2 cm mass in the upper central right breast
T36	PROBLEM 953 987	a 0.4 cm anterior satellite lesion
T37	PROBLEM 1029 1054	additional ductal disease
T38	PROBLEM 1056 1114	disease within the nipple and prominent right axillary LNs
T39	PROBLEM 1129 1139	some delay
T40	TEST 1143 1158	the outside MRI
T41	PROBLEM 1216 1240	the enlarged lymph nodes
T42	TEST 1273 1294	an axillary LN biopsy
T43	TREATMENT 1402 1416	an egg harvest
T44	PROBLEM 1440 1460	3 fertilized embryos
T45	TREATMENT 1494 1513	another egg harvest
T46	TEST 1548 1563	an axillary FNA
T47	TEST 1580 1588	the node
T48	PROBLEM 1606 1623	metastatic cancer
T49	TEST 1625 1631	PET/CT
T50	PROBLEM 1663 1697	a hypermetabolic right breast mass
T51	PROBLEM 1717 1754	an enlarged right axillary lymph node
T52	PROBLEM 1767 1828	other subcentimeter, asymmetric right subpectoral lymph nodes
T53	PROBLEM 1834 1850	low-level uptake
T54	PROBLEM 1867 1898	a hyperdense 0.7 cm falx lesion
T55	PROBLEM 1913 1955	a partially calcified 
 falcine meningioma
T56	PROBLEM 1959 1975	dural metastasis
T57	TEST 1991 2003	an MRI brain
T58	PROBLEM 2021 2039	a dural metastasis
T59	TEST 2041 2048	The MRI
T60	PROBLEM 2056 2099	a 0.5 cm right parafalcine dural-based mass
T61	PROBLEM 2112 2124	a meningioma
T62	PROBLEM 2170 2181	this lesion
T63	TEST 2198 2204	biopsy
T64	TEST 2238 2246	a biopsy
T65	PROBLEM 2270 2276	morbid
T66	PROBLEM 2310 2321	this lesion
T67	PROBLEM 2328 2346	metastatic disease
T68	TREATMENT 2386 2406	a partial mastectomy
T69	TREATMENT 2411 2415	ALND
T70	TREATMENT 2491 2500	treatment
T71	TREATMENT 2516 2537	her treatment options
T72	TREATMENT 2619 2632	her treatment
T73	TREATMENT 2651 2663	chemotherapy
T74	PROBLEM 2725 2738	Breast cancer
T75	TEST 2764 2773	Mammogram
T76	PROBLEM 2803 2859	1.8 cm irregular hyperdense mass in the the right breast
T77	PROBLEM 2874 2909	indeterminate prominent axillary LN
T78	PROBLEM 2939 2964	malignancy in left breast
T79	TEST 2989 3004	Right breast US
T80	PROBLEM 3011 3051	1.8x1.4x1.7 cm irregular hypoechoic mass
T81	PROBLEM 3075 3112	2 non enlarged prominent axillary LN.
T82	TEST 3125 3146	US guided core biopsy
T83	TEST 3148 3151	IDC
T84	TEST 3153 3155	ER
T85	TEST 3167 3169	PR
T86	TEST 3181 3185	HER2
T87	TEST 3189 3192	IHC
T88	TEST 3210 3214	Ki67
T89	TEST 3236 3246	MRI breast
T90	PROBLEM 3248 3281	Dominant biopsy-proven malignancy
T91	PROBLEM 3332 3364	0.4 cm anterior satellite lesion
T93	PROBLEM 3427 3452	disease within the nipple
T94	PROBLEM 3543 3557	an enlarged LN
T95	TEST 3645 3651	Biopsy
T96	PROBLEM 3662 3682	Metastatic carcinoma
T97	TEST 3694 3700	PET/CT
T98	PROBLEM 3702 3734	Hypermetabolic right breast mass
T99	PROBLEM 3739 3758	axillary lymph node
T100	PROBLEM 3775 3795	known metastatic IDC
T101	PROBLEM 3797 3858	Other subcentimeter, asymmetric right subpectoral lymph nodes
T102	PROBLEM 3864 3880	low-level uptake
T103	PROBLEM 3919 3937	metastatic disease
T104	PROBLEM 3939 3968	Hyperdense 0.7 cm falx lesion
T105	PROBLEM 3984 4024	a partially calcified falcine meningioma
T106	PROBLEM 4034 4050	dural metastasis
T107	TEST 4094 4103	brain MRI
T108	TEST 4108 4159	further evaluation.Hypermetabolic right breast mass
T109	TEST 4189 4221	hypermetabolic right axillary LN
T110	TEST 4250 4259	MRI brain
T111	PROBLEM 4261 4300	5 mm right parafalcine dural-based mass
T112	PROBLEM 4316 4328	a meningioma
T113	PROBLEM 4339 4361	dural-based metastasis
T114	TREATMENT 4406 4424	Partial mastectomy
T115	TREATMENT 4478 4510	fertility preservation procedure
T116	TREATMENT 4563 4570	surgery
T117	PROBLEM 4628 4641	Breast cancer
T118	PROBLEM 4647 4661	Hypothyroidism
T119	TREATMENT 4722 4738	CESAREAN SECTION
T120	TREATMENT 4749 4780	egg retrieval         Allergies
T121	PROBLEM 4803 4818	Known Allergies
T122	TREATMENT 4863 4878	cholecalciferol
T123	TREATMENT 4880 4909	vitamin D3, (VITAMIN D3 ORAL)
T124	TREATMENT 4942 4964	  multivitamin tablet
T125	TREATMENT 5015 5024	SYNTHROID
T126	TREATMENT 5090 5113	acetaminophen (TYLENOL)
T127	PROBLEM 5206 5210	Pain
T128	TREATMENT 5287 5311	docusate sodium (COLACE)
T129	TREATMENT 5393 5402	oxycodone
T130	PROBLEM 5414 5426	constipation
T131	TREATMENT 5502 5535	HYDROcodone-acetaminophen (NORCO)
T132	PROBLEM 5611 5615	Pain
T133	TREATMENT 5691 5715	ibuprofen (ADVIL,MOTRIN)
T134	PROBLEM 5805 5809	Pain
T135	TREATMENT 5887 5905	LORazepam (ATIVAN)
T136	PROBLEM 5976 5983	Anxiety
T137	TREATMENT 6004 6026	oxyCODONE (ROXICODONE)
T138	PROBLEM 6116 6120	Pain
T139	TREATMENT 6226 6237	medications
T140	TREATMENT 6317 6336	oral contraceptives
T141	PROBLEM 6381 6394	breast cancer
T142	PROBLEM 6719 6732	Breast cancer
T143	PROBLEM 6786 6797	sore throat
T144	PROBLEM 6799 6815	nasal congestion
T145	PROBLEM 6817 6831	vision changes
T146	PROBLEM 6833 6838	cough
T147	PROBLEM 6840 6850	chest pain
T148	PROBLEM 6852 6859	dyspnea
T149	PROBLEM 6861 6867	nausea
T150	PROBLEM 6869 6877	vomiting
T151	PROBLEM 6879 6893	abdominal pain
T152	PROBLEM 6895 6904	headaches
T153	PROBLEM 6906 6912	fevers
T154	PROBLEM 6918 6953	change in bladder or bowel function
T155	PROBLEM 7105 7113	distress
T156	TEST 7115 7117	BP
T157	TEST 7127 7132	Pulse
T158	TEST 7139 7143	Temp
T159	TEST 7149 7150	C
T160	TEST 7170 7174	Resp
T161	TEST 7181 7183	Ht
T162	TEST 7204 7206	Wt
T163	TEST 7233 7236	LMP
T164	TEST 7251 7255	SpO2
T165	TEST 7263 7266	BMI
T166	TEST 7374 7399	extraocular eye movements
T167	PROBLEM 7463 7470	lesions
T168	PROBLEM 7490 7512	significant adenopathy
T169	PROBLEM 7530 7554	palpable lymphadenopathy
T170	PROBLEM 7559 7577	hepatosplenomegaly
T171	TEST 7596 7608	auscultation
T172	PROBLEM 7613 7620	wheezes
T173	PROBLEM 7683 7690	murmurs
T174	PROBLEM 7708 7717	nontender
T175	PROBLEM 7719 7731	nondistended
T176	PROBLEM 7736 7742	masses
T177	PROBLEM 7746 7758	organomegaly
T178	TEST 7770 7781	breast exam
T179	TEST 7821 7830	Back exam
T180	PROBLEM 7858 7868	tenderness
T181	PROBLEM 7870 7884	palpable spasm
T182	PROBLEM 7888 7892	pain
T183	PROBLEM 7954 7968	focal findings
T184	PROBLEM 7972 7989	movement disorder
T185	PROBLEM 8018 8034	joint tenderness
T186	PROBLEM 8036 8045	deformity
T187	PROBLEM 8049 8057	swelling
T188	TEST 8073 8090	peripheral pulses
T189	PROBLEM 8102 8113	pedal edema
T190	PROBLEM 8125 8131	rashes
T191	PROBLEM 8136 8159	suspicious skin lesions
T192	TEST 8295 8307	POCT glucose
T193	TEST 8309 8320	Fingerstick
T194	TEST 8349 8356	Glucose
T195	TEST 8358 8372	meter download
T196	TEST 8385 8404	mg/dL       Imaging
T197	TEST 8514 8516	MR
T198	PROBLEM 8602 8634	Invasive ductal breast carcinoma
T199	PROBLEM 8640 8670	axillary lymph node metastasis
T200	TEST 8684 8690	PET/CT
T201	TEST 8714 8750	Multiple sequences through the brain
T202	TREATMENT 8800 8824	gadobutrol (Gadavist) IV
T203	PROBLEM 8836 8919	Homogenously-enhancing, partially calcified 5 mm right parafalcine extra-axial mass
T204	PROBLEM 8925 8941	dural attachment
T205	PROBLEM 8955 8997	a dural calcification of the anterior falx
T206	PROBLEM 9019 9039	abnormal enhancement
T207	PROBLEM 9090 9123	abnormal enhancement of the brain
T208	PROBLEM 9125 9174	Heterogenous skull base and calvarial bone marrow
T209	PROBLEM 9195 9207	focal lesion
T210	PROBLEM 9212 9259	abnormal reduced diffusion within the calvarium
T211	PROBLEM 9295 9336	Left maxillary sinus mucus retention cyst
T212	PROBLEM 9342 9381	5 mm right parafalcine dural-based mass
T213	PROBLEM 9397 9409	a meningioma
T214	PROBLEM 9420 9442	dural-based metastasis
T215	TEST 9476 9493	follow-up imaging
T216	TEST 9600 9606	PET/CT
T217	TREATMENT 9607 9636	Whole Body (vertex to thighs)
T218	TEST 9786 9793	Staging
T219	PROBLEM 9840 9906	right invasive ductal carcinoma metastatic to axillary lymph nodes
T220	PROBLEM 9921 9947	distant metastatic disease
T221	TEST 10124 10137	diagnostic CT
T222	TEST 10174 10194	an emission PET scan
T223	TREATMENT 10220 10233	FDG injection
T224	TEST 10236 10246	PET images
T225	TEST 10284 10308	the CT transmission data
T226	TEST 10311 10317	PET/CT
T227	TEST 10354 10371	A rotating 3D MIP
T228	TEST 10495 10514	fused PET/CT images
T229	TEST 10539 10553	the PET images
T230	TEST 10556 10586	Patient's random blood glucose
T231	TREATMENT 10602 10615	FDG injection
T232	TEST 10679 10686	CTDIvol
T233	TEST 10748 10769	the cerebellar SUVmax
T234	PROBLEM 10799 10812	Index lesions
T235	PROBLEM 10817 10849	Hypermetabolic right breast mass
T236	TEST 10873 10880	SUV max
T237	PROBLEM 10911 10958	Mildly hypermetabolic right axillary lymph node
T238	TEST 10976 10983	SUV max
T239	TEST 11001 11006	image
T240	TEST 11011 11022	Lymph nodes
T241	PROBLEM 11024 11086	Additional prominent, asymmetric right subpectoral lymph nodes
T242	PROBLEM 11092 11120	low-level radiotracer uptake
T243	PROBLEM 11132 11142	metastases
T244	PROBLEM 11176 11186	metastases
T245	PROBLEM 11195 11217	Hyperdense 7 mm lesion
T246	PROBLEM 11342 11378	an 8 mm calcified falcine meningioma
T247	PROBLEM 11390 11400	metastases
T248	PROBLEM 11449 11470	symmetric, FDG uptake
T249	PROBLEM 11554 11565	mass effect
T250	TEST 11574 11586	these images
T251	TEST 11616 11619	MRI
T252	PROBLEM 11647 11688	intracranial and/or skull base metastases
T253	PROBLEM 11813 11842	physiologic pelvic free fluid
T254	PROBLEM 11844 11868	Small left ovarian cysts
T255	PROBLEM 11964 11996	Hypermetabolic right breast mass
T256	PROBLEM 12001 12020	axillary lymph node
T257	PROBLEM 12037 12079	known metastatic invasive ductal carcinoma
T258	PROBLEM 12081 12142	Other subcentimeter, asymmetric right subpectoral lymph nodes
T259	PROBLEM 12148 12164	low-level uptake
T260	PROBLEM 12201 12219	metastatic disease
T261	PROBLEM 12224 12251	Hyperdense 7 mm falx lesion
T262	PROBLEM 12276 12316	a partially calcified falcine meningioma
T263	PROBLEM 12326 12342	dural metastasis
T264	TEST 12386 12395	brain MRI
T265	TEST 12400 12418	further evaluation
T266	TEST 12420 12430	This study
T267	TEST 12741 12774	the right axillary lymph node FNA
T268	PROBLEM 12793 12813	metastatic carcinoma
T269	TEST 12905 12921	imaging findings
T270	TREATMENT 12933 12972	continued surgical/oncologic management
T271	PROBLEM 12977 13002	known right breast cancer
T272	TEST 13264 13274	Ultrasound
T273	TEST 13348 13375	Diagnostic right ultrasound
T274	PROBLEM 13473 13489	right breast IDC
T275	TEST 13495 13501	biopsy
T276	PROBLEM 13526 13560	Enlarged right axillary lymph node
T277	TEST 13564 13574	ultrasound
T278	TREATMENT 13587 13596	Procedure
T279	PROBLEM 13660 13664	pain
T280	PROBLEM 13666 13675	infection
T281	PROBLEM 13677 13685	bleeding
T282	PROBLEM 13705 13720	targeted lesion
T283	TREATMENT 13740 13760	further intervention
T284	TEST 13765 13784	diagnostic purposes
T285	TREATMENT 13803 13827	post-biopsy marking clip
T286	PROBLEM 13972 13995	the enlarged lymph node
T287	TREATMENT 14136 14148	1% Xylocaine
T288	TREATMENT 14157 14168	epinephrine
T289	TREATMENT 14170 14182	a 20G needle
T290	TREATMENT 14292 14305	a 25G  needle
T291	TREATMENT 14314 14331	this first needle
T292	TREATMENT 14366 14380	This insertion
T293	TEST 14454 14466	a microscope
T294	TEST 14509 14521	the specimen
T295	TREATMENT 14567 14593	A post biopsy marking clip
T296	TREATMENT 14626 14640	its deployment
T297	TEST 14642 14662	Subsequent mammogram
T298	TREATMENT 14676 14706	the coil shaped Hydromark clip
T299	PROBLEM 14748 14799	the previously biopsied right breast malignant mass
T300	TREATMENT 14805 14811	a clip
T301	TREATMENT 14835 14848	the procedure
T302	TEST 15059 15099	Ultrasound guided fine needle aspiration
T303	PROBLEM 15103 15140	an enlarged right axillary lymph node
T304	TEST 15144 15158	Final cytology
T305	TEST 15395 15428	the right axillary lymph node FNA
T306	PROBLEM 15447 15467	metastatic carcinoma
T307	TEST 15559 15575	imaging findings
T308	TREATMENT 15587 15626	continued surgical/oncologic management
T309	PROBLEM 15631 15656	known right breast cancer
T310	TEST 15920 15930	Ultrasound
T311	TEST 16004 16031	Diagnostic right ultrasound
T312	PROBLEM 16129 16145	right breast IDC
T313	TEST 16151 16157	biopsy
T314	PROBLEM 16182 16216	Enlarged right axillary lymph node
T315	TEST 16220 16230	ultrasound
T316	TREATMENT 16243 16252	Procedure
T317	PROBLEM 16316 16320	pain
T318	PROBLEM 16322 16331	infection
T319	PROBLEM 16333 16341	bleeding
T320	PROBLEM 16359 16374	targeted lesion
T321	TREATMENT 16394 16414	further intervention
T322	TEST 16419 16438	diagnostic purposes
T323	TREATMENT 16457 16481	post-biopsy marking clip
T324	PROBLEM 16626 16649	the enlarged lymph node
T325	TREATMENT 16790 16802	1% Xylocaine
T326	TREATMENT 16811 16822	epinephrine
T327	TREATMENT 16824 16836	a 20G needle
T328	TREATMENT 16946 16959	a 25G  needle
T329	TREATMENT 16968 16985	this first needle
T330	TREATMENT 17020 17034	This insertion
T331	TEST 17108 17120	a microscope
T332	TEST 17163 17175	the specimen
T333	TREATMENT 17221 17247	A post biopsy marking clip
T334	TREATMENT 17280 17294	its deployment
T335	TEST 17296 17316	Subsequent mammogram
T336	TREATMENT 17330 17360	the coil shaped Hydromark clip
T337	PROBLEM 17402 17453	the previously biopsied right breast malignant mass
T338	TREATMENT 17459 17465	a clip
T339	TREATMENT 17489 17502	the procedure
T340	TEST 17715 17755	Ultrasound guided fine needle aspiration
T341	PROBLEM 17759 17796	an enlarged right axillary lymph node
T342	TEST 17800 17814	Final cytology
T343	TEST 17922 17961	Biomedical Imaging    Breast Ultrasound
T344	TEST 18027 18031	Exam
T345	TEST 18036 18067	Limited right breast ultrasound
T346	PROBLEM 18109 18144	recently diagnosed right breast IDC
T347	TEST 18150 18156	biopsy
T348	TEST 18197 18222	right axillary ultrasound
T349	TEST 18236 18253	Prior examination
T350	PROBLEM 18330 18352	an enlarged lymph node
T351	TEST 18504 18525	Ultrasound guided FNA
T352	PROBLEM 18529 18567	the enlarged right axillary lymph node
T353	TEST 18604 18620	this examination
T354	PROBLEM 19111 19134	Rigth axilla lymph node
T355	TEST 19136 19165	fine needle aspiration biopsy
T356	TEST 19228 19257	fine needle aspiration biopsy
T357	PROBLEM 19259 19280	Metastatic  carcinoma
T358	TEST 19470 19506	Ultrasound guided needle core biopsy
T359	PROBLEM 19508 19538	Infiltrating  Ductal Carcinoma
T360	TEST 19739 19756	LARGE CORE BIOPSY
T361	PROBLEM 19761 19786	INVASIVE DUCTAL CARCINOMA
T362	TEST 19861 19882	PROGESTERONE RECEPTOR
T363	TEST 20000 20005	ratio
T364	PROBLEM 20160 20187	HER neg right breast cancer
T365	PROBLEM 20193 20216	axillary LN involvement
T366	PROBLEM 20225 20238	Breast cancer
T367	TREATMENT 20270 20277	surgery
T368	TEST 20303 20314	her imaging
T369	PROBLEM 20392 20414	lymph node involvement
T370	TREATMENT 20453 20474	adjuvant chemotherapy
T371	TREATMENT 20490 20506	hormonal therapy
T372	PROBLEM 20525 20535	her cancer
T373	PROBLEM 20539 20564	hormone receptor positive
T374	PROBLEM 20568 20591	locally advanced tumors
T375	PROBLEM 20619 20633	the tumor size
T376	PROBLEM 20648 20659	lymph nodes
T377	TREATMENT 20703 20738	an anthracycline containing regimen
T378	TREATMENT 20767 20791	neoadjuvant chemotherapy
T379	PROBLEM 20810 20823	node positive
T380	PROBLEM 20827 20858	locally advanced breast cancers
T381	TREATMENT 20895 20920	breast conserving surgery
T382	TREATMENT 20929 20950	neoadjuvant treatment
T383	PROBLEM 20990 21004	the tumor size
T384	PROBLEM 21016 21033	nodal involvement
T385	PROBLEM 21063 21072	her tumor
T386	TREATMENT 21124 21136	chemotherapy
T387	TREATMENT 21155 21162	surgery
T388	TREATMENT 21212 21218	trials
T389	TEST 21375 21394	the validation data
T390	TREATMENT 21476 21486	Mammaprint
T391	PROBLEM 21635 21663	clinical higher risk cancers
T392	TREATMENT 21673 21693	traditional measures
T393	TEST 21704 21714	tumor size
T394	PROBLEM 21716 21743	grade and lymph node status
T395	PROBLEM 21749 21761	whose tumors
T396	TREATMENT 21859 21871	chemotherapy
T397	TREATMENT 21877 21889	chemotherapy
T398	TREATMENT 21972 21984	chemotherapy
T399	TEST 22113 22118	NSABP
T400	TREATMENT 22280 22304	a standard TaxAC regimen
T401	PROBLEM 22332 22348	invasive disease
T402	TEST 22371 22385	A hazard ratio
T403	TEST 22387 22389	HR
T404	TREATMENT 22425 22430	TaxAC
T405	PROBLEM 22465 22468	TC6
T406	TEST 22508 22514	the HR
T407	TEST 22530 22535	TaxAC
T408	TEST 22654 22663	year IDFS
T409	TEST 22678 22681	TC6
T410	TEST 22700 22705	TaxAC
T411	TEST 22881 22883	TC
T412	TEST 22892 22897	TaxAC
T413	PROBLEM 22930 22952	3 positive lymph nodes
T414	PROBLEM 22954 22976	the difference in IDFS
T415	TREATMENT 23048 23060	chemotherapy
T416	PROBLEM 23080 23096	3 positive nodes
T417	TREATMENT 23140 23175	an anthracycline containing regimen
T418	PROBLEM 23193 23207	the toxicities
T419	TREATMENT 23224 23232	Taxotere
T420	TREATMENT 23237 23244	Cytoxan
T421	PROBLEM 23273 23282	infection
T422	PROBLEM 23284 23293	hair loss
T423	PROBLEM 23295 23302	fatigue
T424	PROBLEM 23323 23338	ovarian failure
T425	TREATMENT 23357 23364	taxanes
T426	PROBLEM 23400 23410	neuropathy
T427	TREATMENT 23504 23517	scalp cooling
T428	TREATMENT 23528 23540	the Dignicap
T429	TREATMENT 23545 23561	Penguin Cold Cap
T430	TREATMENT 23598 23610	chemotherapy
T431	TREATMENT 23678 23696	CDK 4/6 inhibitors
T432	PROBLEM 23705 23724	the PALLAS and JPBE
T433	TREATMENT 23793 23802	treatment
T434	TREATMENT 23808 23824	hormonal therapy
T435	TREATMENT 23870 23879	radiation
T436	TREATMENT 23913 23929	hormonal therapy
T437	PROBLEM 23934 23946	side effects
T438	TREATMENT 24035 24049	egg harvesting
T439	TREATMENT 24249 24260	egg harvest
T440	TREATMENT 24301 24308	surgery
T441	TREATMENT 24323 24330	surgery
T442	TREATMENT 24399 24410	medications
T443	TREATMENT 24571 24593	lifestyle modification
T444	PROBLEM 24595 24603	symptoms
T445	TREATMENT 24608 24627	therapeutic options
T446	BiomarkerName 64 80	hormone receptor
A1	HistoryVal T446 new
A2	EpisodeDescription T446 FirstOccurrence
T447	BiomarkerResult 81 89	positive
A3	HistoryVal T447 new
A4	EpisodeDescription T447 FirstOccurrence
A5	BiomarkerResultVal T447 Positive
R1	BiomarkerRel Arg1:T447 Arg2:T446	
T448	BiomarkerName 90 94	HER2
A6	HistoryVal T448 new
A7	EpisodeDescription T448 FirstOccurrence
T449	BiomarkerResult 95 103	negative
A8	HistoryVal T449 new
A9	EpisodeDescription T449 FirstOccurrence
A10	BiomarkerResultVal T449 Negative
R2	BiomarkerRel Arg1:T449 Arg2:T448	
T450	LymphNodeInvolvement 104 108	node
A11	NegationModalityVal T450 affirmed
A12	HistoryVal T450 new
A13	EpisodeDescription T450 FirstOccurrence
T451	ClinicalCondition 124 137	breast cancer
A14	ContinuityVal T451 new
T452	Site 118 123	right
R3	SiteOf Arg1:T452 Arg2:T451	
R4	TumorDesc TumorDetails:T451 Desc:T448	
R5	TumorDesc TumorDetails:T451 Desc:T446	
R6	TumorDesc TumorDetails:T451 Desc:T450	
T453	ProcedureName 170 177	surgery
A15	NegationModalityVal T453 planned_in_future
A16	IntentVal T453 treatment-curative
A17	TreatmentTypeVal T453 local
T454	Datetime 181 189	11/05/17
R7	HappensAtOnDuring Arg1:T453 Arg2:T454	
T455	TreatmentType 213 230	treatment options
T456	Radiology 281 290	mammogram
A18	IntentVal T456 unclear
T457	Datetime 325 333	09/24/17
R8	HappensAtOnDuring Arg1:T456 Arg2:T457	
T458	Site 396 402	breast
T459	Laterality 390 395	right
R9	LateralityOfSite Arg1:T459 Arg2:T458	
T460	Size 350 356	1.8 cm
T461	RadPathResult 357 382	irregular hyperdense mass
A19	RadPathResultVal T461 InitialCancerDiagnosis
R10	ResultOfTest Desc:T461 Test:T456	
R11	SiteOf Arg1:T458 Arg2:T461	
R12	TestOrProcedureReveals Test:T456 Desc:T460	
T462	ClinicalCondition 442 452	malignancy
A20	NegationModalityVal T462 negated
T463	Site 461 467	breast
T464	Laterality 456 460	left
R13	LateralityOfSite Arg1:T464 Arg2:T463	
R14	SiteOf Arg1:T463 Arg2:T462	
R15	TestOrProcedureReveals Test:T456 Desc:T462	
T465	Radiology 469 471	US
A21	IntentVal T465 diagnosis
T466	RadPathResult 490 515	irregular hypoechoic mass
A22	RadPathResultVal T466 InitialCancerDiagnosis
T467	Size 483 489	1.7 cm
R16	TestOrProcedureReveals Test:T465 Desc:T467	
R17	ResultOfTest Desc:T466 Test:T465	
T468	Site 523 537	11:00 position
R18	SiteOf Arg1:T468 Arg2:T466	
T469	LymphNodeInvolvement 549 550;570 573	2 LNs
T470	Site 561 569	axillary
R19	SiteOf Arg1:T470 Arg2:T469	
T471	Pathology 575 596	US guided core biopsy
A23	IntentVal T471 diagnosis
T472	Site 604 610	breast
R20	SiteOf Arg1:T472 Arg2:T471	
T473	Datetime 614 622	09/30/17
R21	HappensAtOnDuring Arg1:T471 Arg2:T473	
T474	Histology 632 657	invasive ductal carcinoma
A24	HistoryVal T474 new
A25	EpisodeDescription T474 FirstOccurrence
R22	TestOrProcedureReveals Test:T471 Desc:T474	
T475	BiomarkerName 659 661	ER
A26	HistoryVal T475 new
A27	EpisodeDescription T475 FirstOccurrence
T476	BiomarkerResult 661 671	+ (80-90%)
A28	HistoryVal T476 new
A29	EpisodeDescription T476 FirstOccurrence
A30	BiomarkerResultVal T476 Positive
T477	BiomarkerName 673 675	PR
A31	HistoryVal T477 new
A32	EpisodeDescription T477 FirstOccurrence
T478	BiomarkerResult 675 685	+ (80-90%)
A33	HistoryVal T478 new
A34	EpisodeDescription T478 FirstOccurrence
A35	BiomarkerResultVal T478 Positive
T479	BiomarkerName 687 691	HER2
A36	HistoryVal T479 new
A37	EpisodeDescription T479 FirstOccurrence
T480	BiomarkerResult 706 714	negative
A38	HistoryVal T480 new
A39	EpisodeDescription T480 FirstOccurrence
T481	Pathology 695 698	IHC
T482	Pathology 701 705	FISH
R23	BiomarkerRel Arg1:T475 Arg2:T476	
R24	BiomarkerRel Arg1:T477 Arg2:T478	
R25	BiomarkerRel Arg1:T479 Arg2:T480	
T483	Pathology 717 721	Ki67
T484	RadPathResult 723 729	20-30%
R26	ResultOfTest Desc:T484 Test:T483	
R27	TestOrProcedureReveals Test:T471 Desc:T475	
R28	TestOrProcedureReveals Test:T471 Desc:T477	
R29	TestOrProcedureReveals Test:T471 Desc:T479	
T485	Radiology 845 848	MRI
T486	Site 852 858	breast
R30	SiteOf Arg1:T486 Arg2:T485	
T487	Datetime 872 880	10/03/17
R31	HappensAtOnDuring Arg1:T485 Arg2:T487	
T488	Size 903 909	2.2 cm
T489	RadPathResult 910 914	mass
A40	RadPathResultVal T489 InitialCancerDiagnosis
T490	Site 922 935;942 948	upper central breast
T491	Laterality 936 941	right
R32	LateralityOfSite Arg1:T491 Arg2:T490	
R33	SiteOf Arg1:T490 Arg2:T489	
R34	TestOrProcedureReveals Test:T485 Desc:T488	
R35	ResultOfTest Desc:T489 Test:T485	
T492	Size 955 961	0.4 cm
T493	RadPathResult 962 987	anterior satellite lesion
R36	ResultOfTest Desc:T493 Test:T485	
T494	LymphNodeInvolvement 1111 1114	LNs
T495	Site 1102 1110	axillary
T496	Laterality 1096 1101	right
R37	LateralityOfSite Arg1:T496 Arg2:T495	
R38	SiteOf Arg1:T495 Arg2:T494	
T497	Site 1075 1081	nipple
T498	RadPathResult 1056 1063	disease
T499	RadPathResult 1040 1054	ductal disease
A41	NegationModalityVal T499 uncertain_in_present
A42	NegationModalityVal T498 uncertain_in_present
R39	SiteOf Arg1:T497 Arg2:T498	
R40	ResultOfTest Desc:T499 Test:T485	
R41	ResultOfTest Desc:T498 Test:T485	
R42	TestOrProcedureReveals Test:T485 Desc:T494	
T500	Pathology 1288 1294	biopsy
A43	IntentVal T500 staging
T501	Site 1276 1287	axillary LN
R43	SiteOf Arg1:T501 Arg2:T500	
T502	LymphNodeInvolvement 1229 1240	lymph nodes
T503	ProcedureName 1405 1416	egg harvest
A44	IntentVal T503 others
T504	ProcedureName 1502 1513	egg harvest
A45	IntentVal T504 others
T505	Pathology 1560 1563	FNA
A46	IntentVal T505 staging
T506	Site 1551 1559	axillary
T507	Datetime 1567 1575	10/28/17
R44	SiteOf Arg1:T506 Arg2:T505	
R45	HappensAtOnDuring Arg1:T505 Arg2:T507	
T508	Metastasis 1606 1623	metastatic cancer
T509	LymphNodeInvolvement 1584 1588	node
R46	TestOrProcedureReveals Test:T505 Desc:T509	
R47	TestOrProcedureReveals Test:T505 Desc:T508	
T510	Radiology 1625 1631	PET/CT
A47	IntentVal T510 staging
T511	Datetime 1645 1653	10/31/17
R48	HappensAtOnDuring Arg1:T510 Arg2:T511	
T512	RadPathResult 1665 1679;1693 1697	hypermetabolic mass
A48	RadPathResultVal T512 InitialCancerDiagnosis
T513	Site 1686 1692	breast
T514	Laterality 1680 1685	right
T515	Size 1699 1711	2.1 x 1.6 cm
T516	LymphNodeInvolvement 1744 1754	lymph node
A49	HistoryVal T516 new
A50	EpisodeDescription T516 FirstOccurrence
T517	Site 1735 1743	axillary
T518	Laterality 1729 1734	right
R49	LateralityOfSite Arg1:T518 Arg2:T517	
R50	SiteOf Arg1:T517 Arg2:T516	
R51	ResultOfTest Desc:T512 Test:T510	
R52	SiteOf Arg1:T513 Arg2:T512	
R53	LateralityOfSite Arg1:T514 Arg2:T513	
R54	TestOrProcedureReveals Test:T510 Desc:T515	
R55	TestOrProcedureReveals Test:T510 Desc:T516	
T519	LymphNodeInvolvement 1817 1828	lymph nodes
T520	Site 1805 1816	subpectoral
T521	Laterality 1799 1804	right
T522	Size 1773 1786	subcentimeter
R56	LateralityOfSite Arg1:T521 Arg2:T520	
R57	SiteOf Arg1:T520 Arg2:T519	
R58	TestOrProcedureReveals Test:T510 Desc:T522	
R59	TestOrProcedureReveals Test:T510 Desc:T519	
T523	RadPathResult 1869 1879;1887 1898	hyperdense falx lesion
T524	Size 1880 1886	0.7 cm
R60	ResultOfTest Desc:T523 Test:T510	
R61	TestOrProcedureReveals Test:T510 Desc:T524	
T525	Metastasis 1965 1975	metastasis
A51	NegationModalityVal T525 uncertain_in_past
T526	Site 1959 1964	dural
R62	SiteOf Arg1:T526 Arg2:T525	
R63	TestOrProcedureReveals Test:T510 Desc:T525	
T527	Radiology 1994 1997	MRI
A52	IntentVal T527 staging
T528	Site 1998 2003	brain
T529	Metastasis 2029 2039	metastasis
T530	Site 2023 2028	dural
R64	SiteOf Arg1:T530 Arg2:T529	
R65	SiteOf Arg1:T528 Arg2:T527	
A53	NegationModalityVal T529 uncertain_in_past
R66	TestOrProcedureConductedForProblem Test:T527 Prob:T529	
T531	Radiology 2045 2048	MRI
A54	IntentVal T531 diagnosis
T532	RadPathResult 2095 2099	mass
T533	Size 2058 2064	0.5 cm
T534	Site 2071 2094	parafalcine dural-based
T535	Laterality 2065 2070	right
R67	LateralityOfSite Arg1:T535 Arg2:T534	
R68	SiteOf Arg1:T534 Arg2:T532	
R69	TestOrProcedureReveals Test:T531 Desc:T533	
R70	ResultOfTest Desc:T532 Test:T531	
T536	Histology 2114 2124	meningioma
R71	ResultOfTest Desc:T536 Test:T531	
A55	NegationModalityVal T536 uncertain_in_present
T537	ProcedureName 2198 2204	biopsy
A56	IntentVal T537 diagnosis
T538	ProcedureName 2240 2246	biopsy
A57	IntentVal T538 diagnosis
T539	Symptom 2270 2276	morbid
R72	ConditionOrTreatmentCausesProblem Treatment:T538 Prob:T539	
T540	Metastasis 2328 2338	metastatic
A58	NegationModalityVal T540 uncertain_in_present
T541	ProcedureName 2388 2406	partial mastectomy
A59	NegationModalityVal T541 planned_in_future
A60	IntentVal T541 treatment-curative
A61	TreatmentTypeVal T541 local
T542	ProcedureName 2411 2415	ALND
A62	NegationModalityVal T542 planned_in_future
A63	IntentVal T542 treatment-curative
A64	TreatmentTypeVal T542 local
T543	Datetime 2433 2441	11/05/17
R73	HappensAtOnDuring Arg1:T541 Arg2:T543	
R74	HappensAtOnDuring Arg1:T542 Arg2:T543	
T546	TreatmentType 2651 2663	chemotherapy
A66	NegationModalityVal T546 hypothetical_in_future
A67	TreatmentTypeVal T546 adjuvant
A68	TreatmentIntentVal T546 curative
T548	ClinicalCondition 2725 2738	Breast cancer
T549	Datetime 2739 2749	11/03/2017
R75	HappensAtOnDuring Arg1:T548 Arg2:T549	
T550	Radiology 2764 2773	Mammogram
T551	Datetime 2754 2762	09/24/17
R76	HappensAtOnDuring Arg1:T550 Arg2:T551	
T552	RadPathResult 2810 2835	irregular hyperdense mass
A69	RadPathResultVal T552 InitialCancerDiagnosis
T553	Size 2803 2809	1.8 cm
A70	HistoryVal T553 new
A71	EpisodeDescription T553 FirstOccurrence
T554	Site 2853 2868	breast at 11:00
T555	Laterality 2847 2852	right
R77	LateralityOfSite Arg1:T555 Arg2:T554	
R78	SiteOf Arg1:T554 Arg2:T552	
R79	ResultOfTest Desc:T552 Test:T550	
R80	TestOrProcedureReveals Test:T550 Desc:T553	
T556	LymphNodeInvolvement 2907 2909	LN
T557	Site 2898 2906	axillary
R81	SiteOf Arg1:T557 Arg2:T556	
R82	TestOrProcedureReveals Test:T550 Desc:T556	
T558	Site 2958 2964	breast
T559	Laterality 2953 2957	left
R83	LateralityOfSite Arg1:T559 Arg2:T558	
T560	ClinicalCondition 2939 2949	malignancy
A72	NegationModalityVal T560 negated
R84	SiteOf Arg1:T558 Arg2:T560	
R85	TestOrProcedureReveals Test:T550 Desc:T560	
T561	Datetime 2968 2976	09/24/17
T562	Radiology 2978 2980	US
A73	IntentVal T562 diagnosis
T563	Site 2981 2987	breast
R86	SiteOf Arg1:T563 Arg2:T562	
R87	HappensAtOnDuring Arg1:T562 Arg2:T561	
T564	Site 2995 3001;3059 3073	breast 11:00 position
T565	Laterality 2989 2994	Right
T566	RadPathResult 3026 3051	irregular hypoechoic mass
A74	RadPathResultVal T566 InitialCancerDiagnosis
T567	Size 3011 3025	1.8x1.4x1.7 cm
A75	HistoryVal T567 new
A76	EpisodeDescription T567 FirstOccurrence
R89	ResultOfTest Desc:T566 Test:T562	
R90	SiteOf Arg1:T564 Arg2:T566	
R92	TestOrProcedureReveals Test:T562 Desc:T567	
T568	LymphNodeInvolvement 3075 3076;3109 3111	2 LN
A77	HistoryVal T568 new
A78	EpisodeDescription T568 FirstOccurrence
T569	Site 3100 3108	axillary
R93	SiteOf Arg1:T569 Arg2:T568	
R94	TestOrProcedureReveals Test:T562 Desc:T568	
T570	Datetime 3115 3123	09/30/17
T571	Pathology 3125 3146	US guided core biopsy
A79	IntentVal T571 diagnosis
T572	Histology 3148 3151	IDC
A80	HistoryVal T572 new
A81	EpisodeDescription T572 FirstOccurrence
T573	BiomarkerName 3153 3155	ER
A82	HistoryVal T573 new
A83	EpisodeDescription T573 FirstOccurrence
T574	BiomarkerResult 3155 3165	+ (80-90%)
A84	HistoryVal T574 new
A85	EpisodeDescription T574 FirstOccurrence
A86	BiomarkerResultVal T574 Positive
R95	BiomarkerRel Arg1:T573 Arg2:T574	
T575	BiomarkerName 3167 3169	PR
A87	HistoryVal T575 new
A88	EpisodeDescription T575 FirstOccurrence
T576	BiomarkerResult 3169 3179	+ (80-90%)
A89	HistoryVal T576 new
A90	EpisodeDescription T576 FirstOccurrence
A91	BiomarkerResultVal T576 Positive
R96	BiomarkerRel Arg1:T575 Arg2:T576	
T577	BiomarkerName 3181 3185	HER2
A92	HistoryVal T577 new
A93	EpisodeDescription T577 FirstOccurrence
T578	Pathology 3189 3192	IHC
T579	Pathology 3195 3199	FISH
T580	BiomarkerResult 3200 3208	negative
A94	HistoryVal T580 new
A95	EpisodeDescription T580 FirstOccurrence
A96	BiomarkerResultVal T580 Negative
R97	BiomarkerRel Arg1:T577 Arg2:T580	
R98	TestOrProcedureReveals Test:T571 Desc:T572	
R99	TestOrProcedureReveals Test:T571 Desc:T573	
R100	TestOrProcedureReveals Test:T571 Desc:T575	
R101	TestOrProcedureReveals Test:T571 Desc:T577	
T581	Pathology 3210 3214	Ki67
T582	RadPathResult 3216 3222	20-30%
R102	ResultOfTest Desc:T582 Test:T581	
T583	Datetime 3226 3234	10/03/17
T584	Radiology 3236 3239	MRI
A97	IntentVal T584 diagnosis
T585	Site 3240 3246	breast
R103	SiteOf Arg1:T585 Arg2:T584	
R104	HappensAtOnDuring Arg1:T584 Arg2:T583	
T586	ClinicalCondition 3271 3281	malignancy
A98	HistoryVal T586 new
A99	EpisodeDescription T586 FirstOccurrence
T587	Site 3283 3296;3303 3309	upper central breast
T588	Laterality 3297 3302	right
R105	LateralityOfSite Arg1:T588 Arg2:T587	
R106	SiteOf Arg1:T587 Arg2:T586	
T589	Size 3320 3326	2.2 cm
T590	RadPathResult 3348 3364	satellite lesion
T591	Site 3339 3347	anterior
T592	Size 3332 3338	0.4 cm
R107	SiteOf Arg1:T591 Arg2:T590	
R108	TestOrProcedureReveals Test:T584 Desc:T586	
R109	TestOrProcedureReveals Test:T584 Desc:T589	
R110	TestOrProcedureReveals Test:T584 Desc:T592	
T92	RadPathResult 3407 3422	ductal  disease
A100	NegationModalityVal T92 uncertain_in_present
T593	RadPathResult 3427 3434	disease
A101	NegationModalityVal T593 uncertain_in_present
T594	Site 3446 3452	nipple
R112	SiteOf Arg1:T594 Arg2:T593	
R113	ResultOfTest Desc:T92 Test:T584	
R114	ResultOfTest Desc:T593 Test:T584	
T595	LymphNodeInvolvement 3479 3481	LN
T596	Site 3470 3478	axillary
T597	Laterality 3464 3469	right
R115	LateralityOfSite Arg1:T597 Arg2:T596	
R116	SiteOf Arg1:T596 Arg2:T595	
R117	TestOrProcedureReveals Test:T584 Desc:T595	
T598	Site 3489 3495	breast
T599	Laterality 3484 3488	Left
T600	RadPathResult 3497 3505	Negative
A102	RadPathResultVal T600 NoDisease
R118	SiteOf Arg1:T598 Arg2:T600	
R119	LateralityOfSite Arg1:T599 Arg2:T598	
R120	ResultOfTest Desc:T600 Test:T584	
T601	Datetime 3507 3515	10/28/17
T602	Radiology 3517 3519	US
A103	IntentVal T602 staging
T603	Laterality 3527 3532	right
T604	Site 3520 3526	axilla
R121	SiteOf Arg1:T604 Arg2:T602	
R122	LateralityOfSite Arg1:T603 Arg2:T604	
T605	LymphNodeInvolvement 3555 3557	LN
A104	HistoryVal T605 new
A105	EpisodeDescription T605 FirstOccurrence
T606	Size 3568 3580	0.7 x 0.7 cm
T607	Site 3594 3600;3619 3643	axilla 10:00, 14 cm from nipple
T608	Laterality 3588 3593	right
R123	LateralityOfSite Arg1:T608 Arg2:T607	
R125	TestOrProcedureReveals Test:T602 Desc:T605	
R126	TestOrProcedureReveals Test:T602 Desc:T606	
T609	Pathology 3645 3651	Biopsy
T610	Metastasis 3662 3682	Metastatic carcinoma
A106	HistoryVal T610 new
A107	EpisodeDescription T610 FirstOccurrence
R127	TestOrProcedureReveals Test:T609 Desc:T610	
T611	Datetime 3684 3692	10/31/17
T612	Radiology 3694 3700	PET/CT
A108	IntentVal T612 staging
R128	HappensAtOnDuring Arg1:T612 Arg2:T611	
T613	RadPathResult 3702 3716;3730 3734	Hypermetabolic mass
A109	RadPathResultVal T613 InitialCancerDiagnosis
T614	Site 3723 3729	breast
T615	Laterality 3717 3722	right
R129	LateralityOfSite Arg1:T615 Arg2:T614	
R130	SiteOf Arg1:T614 Arg2:T613	
R131	ResultOfTest Desc:T613 Test:T612	
T616	LymphNodeInvolvement 3748 3758	lymph node
A110	HistoryVal T616 new
A111	EpisodeDescription T616 FirstOccurrence
T617	Site 3739 3747	axillary
R132	SiteOf Arg1:T617 Arg2:T616	
R133	TestOrProcedureReveals Test:T612 Desc:T616	
T618	Metastasis 3781 3795	metastatic IDC
A112	HistoryVal T618 new
A113	EpisodeDescription T618 FirstOccurrence
T619	LymphNodeInvolvement 3847 3858	lymph nodes
A114	HistoryVal T619 new
A115	EpisodeDescription T619 FirstOccurrence
T620	Site 3835 3846	subpectoral
T621	Laterality 3831 3832	g
T622	Size 3803 3816	subcentimeter
R134	LateralityOfSite Arg1:T621 Arg2:T620	
R135	SiteOf Arg1:T620 Arg2:T619	
R136	TestOrProcedureReveals Test:T612 Desc:T619	
T623	Metastasis 3919 3937	metastatic disease
T624	RadPathResult 3939 3949;3962 3968	Hyperdense lesion
T625	Site 3957 3961	falx
T626	Size 3950 3956	0.7 cm
R137	SiteOf Arg1:T625 Arg2:T624	
R138	ResultOfTest Desc:T624 Test:T612	
T627	RadPathResult 3986 4005;4014 4024	partially calcified meningioma
A116	NegationModalityVal T627 uncertain_in_present
T628	Site 4006 4013	falcine
R139	SiteOf Arg1:T628 Arg2:T627	
R140	ResultOfTest Desc:T627 Test:T612	
T629	Metastasis 4040 4050	metastasis
T630	Site 4034 4039	dural
R141	SiteOf Arg1:T630 Arg2:T629	
A117	NegationModalityVal T629 uncertain_in_present
R142	TestOrProcedureReveals Test:T612 Desc:T629	
T631	Radiology 4100 4103	MRI
A118	IntentVal T631 staging
T632	Site 4094 4099	brain
R143	SiteOf Arg1:T632 Arg2:T631	
T633	RadPathResult 4127 4141;4155 4159	Hypermetabolic mass
A119	RadPathResultVal T633 InitialCancerDiagnosis
T634	Site 4148 4154	breast
T635	Laterality 4142 4147	right
R144	LateralityOfSite Arg1:T635 Arg2:T634	
R145	SiteOf Arg1:T634 Arg2:T633	
T636	Size 4169 4181	2.1 x 1.6 cm
T637	LymphNodeInvolvement 4189 4203;4219 4221	hypermetabolic LN
T638	Site 4210 4218	axillary
T639	Laterality 4204 4209	right
R146	SiteOf Arg1:T638 Arg2:T637	
R147	LateralityOfSite Arg1:T639 Arg2:T638	
T640	Size 4231 4237	2.8 cm
R148	ResultOfTest Desc:T633 Test:T612	
R149	TestOrProcedureReveals Test:T612 Desc:T637	
R150	TestOrProcedureReveals Test:T612 Desc:T636	
R151	TestOrProcedureReveals Test:T612 Desc:T640	
T641	Datetime 4240 4248	11/03/17
T642	Datetime 4396 4404	11/05/17
T643	Radiology 4250 4253	MRI
A120	IntentVal T643 staging
T644	Site 4254 4259	brain
R152	HappensAtOnDuring Arg1:T643 Arg2:T641	
R153	SiteOf Arg1:T644 Arg2:T643	
T645	RadPathResult 4296 4300	mass
T646	Site 4272 4295	parafalcine dural-based
T647	Laterality 4266 4271	right
T648	Size 4261 4265	5 mm
R154	LateralityOfSite Arg1:T647 Arg2:T646	
R155	SiteOf Arg1:T646 Arg2:T645	
R156	ResultOfTest Desc:T645 Test:T643	
R157	TestOrProcedureReveals Test:T643 Desc:T648	
T649	RadPathResult 4318 4328	meningioma
A121	NegationModalityVal T649 uncertain_in_present
T650	Metastasis 4351 4361	metastasis
T651	Site 4339 4350	dural-based
R158	SiteOf Arg1:T651 Arg2:T650	
A122	NegationModalityVal T650 uncertain_in_present
R159	ResultOfTest Desc:T649 Test:T643	
R160	TestOrProcedureReveals Test:T643 Desc:T650	
T652	ProcedureName 4406 4424	Partial mastectomy
A123	IntentVal T652 treatment-curative
A124	TreatmentTypeVal T652 local
A125	NegationModalityVal T652 planned_in_future
R161	HappensAtOnDuring Arg1:T652 Arg2:T642	
T653	ProcedureName 4478 4500	fertility preservation
A126	IntentVal T653 others
A127	TreatmentTypeVal T653 others
A128	TreatmentCategory T653 Others
T654	Datetime 4511 4521	10/20/2017
R162	HappensAtOnDuring Arg1:T653 Arg2:T654	
T655	TreatmentType 4563 4570	surgery
T656	ClinicalCondition 4628 4641	Breast cancer
T657	ClinicalCondition 4647 4661	Hypothyroidism
A129	ChronicVal T657 chronic
T658	ProcedureName 4722 4738	CESAREAN SECTION
T659	Datetime 4740 4744	2015
R163	HappensAtOnDuring Arg1:T658 Arg2:T659	
T660	ProcedureName 4749 4762	egg retrieval
T661	SectionSkip 4771 4818	Allergies/Contraindications  No Known Allergies
A130	SectionSkipType T661 allergies
T662	SectionSkip 4824 5843;5846 6253	Current Outpatient Prescriptions:     cholecalciferol, vitamin D3, (VITAMIN D3 ORAL), Take by mouth., Disp: , Rfl:     multivitamin tablet, Take 1 tablet by mouth Daily., Disp: , Rfl:     SYNTHROID 112 mcg tablet, Take 112 mcg by mouth Daily. , Disp: , Rfl:     acetaminophen (TYLENOL) 500 mg tablet, Take 2 tablets (1,000 mg total) by mouth every 8 (eight) hours as needed for Pain. (Patient not taking: Reported on 11/06/2017), Disp: 100 tablet, Rfl: 1    docusate sodium (COLACE) 100 mg capsule, Take 1 capsule (100 mg total) by mouth Twice a day. While taking oxycodone to prevent constipation (Patient not taking: Reported on 11/06/2017), Disp: 30 capsule, Rfl: 1    HYDROcodone-acetaminophen (NORCO) 5-325 mg tablet, Take 1 tablet by mouth every 4 (four) hours as needed for Pain. (Patient not taking: Reported on 11/06/2017), Disp: 26 tablet, Rfl: 0    ibuprofen (ADVIL,MOTRIN) 600 mg tablet, Take 1 tablet (600 mg total) by mouth every 8 (eight) hours as needed for Pain. (Patient not taking: Reported on 11/06/2017), Disp: 60 tablet, Rfl: 1    LORazepam (ATIVAN) 0.5 mg tablet, Take 0.5 mg by mouth every 6 (six) hours as needed for Anxiety., Disp: , Rfl:     oxyCODONE (ROXICODONE) 5 mg tablet, Take 1-2 tablets (5-10 mg total) by mouth every 6 (six) hours as needed for Pain. (Patient not taking: Reported on 11/06/2017), Disp: 20 tablet, Rfl: 0  No current facility-administered medications for this visit.
A131	SectionSkipType T662 medications
T663	MedicationRegimen 6317 6336	oral contraceptives
T664	Duration 6304 6309	4 yrs
R164	HappensAtOnDuring Arg1:T663 Arg2:T664	
T665	ClinicalCondition 6338 6344	Menses
T666	Frequency 6350 6357	regular
R165	Temporal Arg1:T665 Arg2:T666	
T667	ClinicalCondition 6381 6394	breast cancer
T668	LivingCondition 6450 6514	lives with her husband, child and extended family in ***** *****
T669	Employment 6528 6532	tech
T670	Tobacco 6569 6581	Never Smoker
A134	NegationModalityVal T670 negated
T671	Tobacco 6606 6616	Never Used
A135	NegationModalityVal T671 negated
T672	ClinicalCondition 6719 6732	Breast cancer
A136	ExperiencerVal T672 family
T673	SectionSkip 7029 7791;7794 8165	Physical Examination: General appearance - alert, well appearing, and in no distress  BP 99/68  | Pulse 65  | Temp 36.1 C (96.9 F) (Oral)  | Resp 18  | Ht 157.5 cm (5' 2")  | Wt 77 kg (169 lb 11.2 oz)  | LMP 10/13/2017  | SpO2 96%  | BMI 31.04 kg/m   Mental status - alert, oriented to person, place, and time  Eyes - pupils equal and reactive, extraocular eye movements intact  Mouth - mucous membranes moist, pharynx normal without lesions  Neck - supple, no significant adenopathy  Lymphatics - no palpable lymphadenopathy, no hepatosplenomegaly  Chest - clear to auscultation, no wheezes, symmetric air entry  Heart - normal rate, regular rhythm, no murmurs  Abdomen - soft, nontender, nondistended, no masses or organomegaly  Breasts - breast exam not done, no axillary LN palpable.   Back exam - full range of motion, no tenderness, palpable spasm or pain on motion  Neurological - alert, oriented, normal speech, no focal findings or movement disorder noted  Musculoskeletal - no joint tenderness, deformity or swelling  Extremities - peripheral pulses normal, no pedal edema  Skin - no rashes, no suspicious skin lesions noted
A137	SectionSkipType T673 physical_exam
T674	SectionSkip 8169 8390	Labs reviewed and discussed with patient:  Results for orders placed or performed during the hospital encounter of 10/31/17   POCT glucose, Fingerstick   Result Value Ref Range    Glucose, meter download 93 70 - 199 mg/dL
A138	SectionSkipType T674 laboratory
T675	Datetime 8502 8512	11/03/2017
T676	Radiology 8514 8516;8523 8548	MR WITH AND WITHOUT CONTRAST
T677	Site 8517 8522	BRAIN
R166	HappensAtOnDuring Arg1:T676 Arg2:T675	
R167	SiteOf Arg1:T677 Arg2:T676	
T678	Radiology 8451 8453;8460 8485	Mr With And Without Contrast
T679	Site 8454 8459	Brain
R168	SiteOf Arg1:T679 Arg2:T678	
R169	HappensAtOnDuring Arg1:T678 Arg2:T675	
T680	Histology 8602 8634	Invasive ductal breast carcinoma
A139	HistoryVal T680 new
A140	EpisodeDescription T680 FirstOccurrence
T681	LymphNodeInvolvement 8649 8670	lymph node metastasis
A141	HistoryVal T681 new
A142	EpisodeDescription T681 FirstOccurrence
T682	Site 8640 8648	axillary
R170	SiteOf Arg1:T682 Arg2:T681	
T683	Radiology 8684 8690	PET/CT
A143	IntentVal T683 staging
T684	Datetime 8691 8701	10/31/2017
R171	HappensAtOnDuring Arg1:T683 Arg2:T684	
T685	SectionSkip 8703 9520	TECHNIQUE: Multiple sequences through the brain were acquired at 3 Tesla. CONTRAST MEDIA: 7.5 ml gadobutrol (Gadavist) IV. FINDINGS: Homogenously-enhancing, partially calcified 5 mm right parafalcine extra-axial mass with dural attachment. Anteriorly, a dural calcification of the anterior falx does not demonstrate abnormal enhancement. Normal brain parenchyma and signal intensity. No abnormal enhancement of the brain. Heterogenous skull base and calvarial bone marrow without evidence of focal lesion. No abnormal reduced diffusion within the calvarium. Normal flow-related signal voids. Left maxillary sinus mucus retention cyst.     5 mm right parafalcine dural-based mass is most likely a meningioma, although dural-based metastasis remains an unlikely possibility; follow-up imaging in 6 months may be helpful
A144	SectionSkipType T685 radiology_report
T686	Radiology 9527 9532	Petct
A145	IntentVal T686 staging
T687	Site 9533 9571	Limited Whole Body Vertex To Mid Thigh
T688	Datetime 9588 9598	10/31/2017
T689	Radiology 9600 9606	PET/CT
A146	IntentVal T689 staging
T690	Site 9607 9636	Whole Body (vertex to thighs)
R172	SiteOf Arg1:T690 Arg2:T689	
R173	HappensAtOnDuring Arg1:T689 Arg2:T688	
R174	SiteOf Arg1:T687 Arg2:T686	
R175	HappensAtOnDuring Arg1:T686 Arg2:T688	
T691	Histology 9846 9871	invasive ductal carcinoma
A147	HistoryVal T691 new
A148	EpisodeDescription T691 FirstOccurrence
T692	Metastasis 9872 9882	metastatic
T693	LymphNodeInvolvement 9895 9906	lymph nodes
A149	HistoryVal T693 new
A150	EpisodeDescription T693 FirstOccurrence
T694	Site 9886 9894	axillary
R176	SiteOf Arg1:T694 Arg2:T693	
T695	Metastasis 9929 9939	metastatic
T11	SectionSkip 9950 11719;11724 12483	CURRENT THERAPY AND DATE INITIATED: None TECHNIQUE:   Patient's fasting time was > 6 hours.  Following intravenous administration of 9.1 mCi of F18-FDG, a contrast enhanced, diagnostic CT was performed. This was followed by an emission PET scan started 60 minutes after FDG injection.  PET images were corrected for attenuation using the CT transmission data.  PET/CT was acquired from vertex to thighs. A rotating 3D MIP, as well as axial, coronal, and sagittal PET images with and without attenuation correction was interpreted.  Acquired and fused PET/CT images were reviewed alongside the PET images.  Patient's random blood glucose at the time of FDG injection was 93 mg/dL.  RADIATION DOSE INDICATORS: 3 exposure event(s), CTDIvol:  2.9 - 10.3 mGy. DLP: 1016 mGy-cm. FINDINGS: For reference, the cerebellar SUVmax is 13.2. Oncologic Findings: Index lesions: 1. Hypermetabolic right breast mass measures 2.1 x 1.6 cm, SUV max 7.7 (series 201, image 81) 2. Mildly hypermetabolic right axillary lymph node measures 2.8 cm, SUV max 2.9 (series 201, image 82) Lymph nodes: Additional prominent, asymmetric right subpectoral lymph nodes with low-level radiotracer uptake. Lungs: No metastases. Abdominal and pelvic organs: No metastases. Bones: Hyperdense 7 mm lesion along the falx projecting rightward with possible dural tail (series 201, image 13). Inferior and anterior to this there is an 8 mm calcified falcine meningioma. Other: No metastases. Non-oncologic findings: Brain:   Unremarkable, symmetric, FDG uptake is seen throughout the cortical gray matter, basal ganglia and the cerebellum.  No mass effect.  While these images appear within normal limits, MRI is recommended to rule out intracranial and/or skull base metastases if clinically indicated. Neck: Otherwise unremarkable. Chest:   Otherwise unremarkable. Abdomen/Pelvis: Trace amount of physiologic pelvic free fluid. Small left ovarian cysts, likely physiologic. Otherwise unremarkable. Musculoskeletal:   Otherwise unremarkable.     1. Hypermetabolic right breast mass and axillary lymph node consistent with known metastatic invasive ductal carcinoma. Other subcentimeter, asymmetric right subpectoral lymph nodes with low-level uptake could represent additional sites of metastatic disease. 2. Hyperdense 7 mm falx lesion is favored to represent a partially calcified falcine meningioma, however dural metastasis is a differential consideration. Recommend brain MRI for further evaluation. This study was reviewed by Dr. ***** ***** of Nuclear Medicine.
A151	SectionSkipType T11 radiology_report
T12	SectionSkip 12484 13235	//ALERT// 2 Report dictated by: ***** *****, MD MS, signed by: ***** ***** *****, MD PhD Department of Radiology and Biomedical Imaging    Place ***** Clip ***** Core, Rt    Addendum Date: 10/30/2017    ===ADDENDUM===Cytology is now available for review of the right axillary lymph node FNA, and demonstrates metastatic carcinoma. Please see pathology report for full details. These malignant results are concordant with imaging findings. Recommend continued surgical/oncologic management for known right breast cancer. Per patient request, Radiology Dr ***** ***** notified the patient of these malignant results at 1535 on 10/29/17. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging
A152	SectionSkipType T12 pathology_report
T696	SectionSkip 13239 13702;13705 15661;15664 17642;17645 17940	Result Date: 10/30/2017  Ultrasound Guided Fine Needle Aspiration: *****/*****/***** 11:53 AM COMPARISON:    Diagnostic right ultrasound 10/28/17 and outside hospital 09/24/17 CLINICAL HISTORY: 36 year old woman with recent diagnosis right breast IDC from biopsy at an outside hospital. Enlarged right axillary lymph node on ultrasound. TECHNIQUE: Procedure was explained in detail to patient.  Risks (including risks of pain, infection, bleeding, non-recovery of targeted lesion, possible need for further intervention for diagnostic purposes), intent to place post-biopsy marking clip, benefits, and alternatives discussed.  All questions were answered.   Written and verbal informed consent obtained.  Under sterile conditions, the enlarged lymph node was re-identified at the 10 o'clock location, 14 cm from the nipple in the posterior right depth  right axilla. Following administration of 1% Xylocaine without epinephrine, a 20G needle was placed under sonographic guidance with its tip just within the lesion. The cytopathologist then inserted a 25G  needle through this first needle with multiple to-and-fro motions. This insertion was repeated 2 more times. The  material was preliminarily reviewed with a microscope by the cytopathologist on site who deemed the specimen adequate.  Material will be further studied. A post biopsy marking clip was placed with confirmation of its deployment. Subsequent mammogram demonstrates the coil shaped Hydromark clip to be in the right axilla. Also noted is the previously biopsied right breast malignant mass with a clip. The patient tolerated the procedure well and left the department in satisfactory condition. She may obtain the results from her referring physician within 4 working days time, and if this is not possible, she may contact this department.      1. Ultrasound guided fine needle aspiration of an enlarged right axillary lymph node 2. Final cytology pending. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    Us Guided Fna, Right    Addendum Date: 10/30/2017    ===ADDENDUM===Cytology is now available for review of the right axillary lymph node FNA, and demonstrates metastatic carcinoma. Please see pathology report for full details. These malignant results are concordant with imaging findings. Recommend continued surgical/oncologic management for known right breast cancer. Per patient request, Radiology Dr ***** ***** notified the patient of these malignant results at 1535 on 10/29/17. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    Result Date: 10/30/2017  Ultrasound Guided Fine Needle Aspiration: *****/*****/***** 11:53 AM COMPARISON:    Diagnostic right ultrasound 10/28/17 and outside hospital 09/24/17 CLINICAL HISTORY: 36 year old woman with recent diagnosis right breast IDC from biopsy at an outside hospital. Enlarged right axillary lymph node on ultrasound. TECHNIQUE: Procedure was explained in detail to patient.  Risks (including risks of pain, infection, bleeding, non-recovery of targeted lesion, possible need for further intervention for diagnostic purposes), intent to place post-biopsy marking clip, benefits, and alternatives discussed.  All questions were answered.   Written and verbal informed consent obtained.  Under sterile conditions, the enlarged lymph node was re-identified at the 10 o'clock location, 14 cm from the nipple in the posterior right depth  right axilla. Following administration of 1% Xylocaine without epinephrine, a 20G needle was placed under sonographic guidance with its tip just within the lesion. The cytopathologist then inserted a 25G  needle through this first needle with multiple to-and-fro motions. This insertion was repeated 2 more times. The  material was preliminarily reviewed with a microscope by the cytopathologist on site who deemed the specimen adequate.  Material will be further studied. A post biopsy marking clip was placed with confirmation of its deployment. Subsequent mammogram demonstrates the coil shaped Hydromark clip to be in the right axilla. Also noted is the previously biopsied right breast malignant mass with a clip. The patient tolerated the procedure well and left the department in satisfactory condition. She may obtain the results from her referring physician within 4 working days time, and if this is not possible, she may contact this department.      1. Ultrasound guided fine needle aspiration of an enlarged right axillary lymph node 2. Final cytology pending. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging
A153	SectionSkipType T696 pathology_report
A154	SectionSkipType T13 radiology_report
T697	Datetime 17993 18003	10/28/2017
T698	Datetime 18016 18026	10/28/2017
T699	Radiology 18057 18067	ultrasound
T700	Site 18050 18056	breast
T701	Laterality 18044 18049	right
R177	LateralityOfSite Arg1:T701 Arg2:T700	
R178	SiteOf Arg1:T700 Arg2:T699	
R179	HappensAtOnDuring Arg1:T699 Arg2:T698	
T702	Histology 18141 18144	IDC
A155	HistoryVal T702 new
A156	EpisodeDescription T702 FirstOccurrence
T703	Site 18134 18140	breast
T704	Laterality 18128 18133	right
R180	SiteOf Arg1:T703 Arg2:T702	
R181	LateralityOfSite Arg1:T704 Arg2:T703	
T705	Pathology 18150 18156	biopsy
A157	IntentVal T705 diagnosis
R182	TestOrProcedureReveals Test:T705 Desc:T702	
T706	Radiology 18212 18222	ultrasound
A158	IntentVal T706 diagnosis
T707	Site 18203 18211	axillary
T708	Laterality 18197 18202	right
R183	LateralityOfSite Arg1:T708 Arg2:T707	
R184	SiteOf Arg1:T707 Arg2:T706	
A159	SectionSkipType T14 pathology_report
T709	Pathology 19470 19506	Ultrasound guided needle core biopsy
A160	IntentVal T709 diagnosis
T710	Histology 19508 19538	Infiltrating  Ductal Carcinoma
A161	HistoryVal T710 new
A162	EpisodeDescription T710 FirstOccurrence
T711	Site 19540 19546;19564 19577	Breast 05:00 o'clock
T712	Laterality 19548 19553	Right
R185	LateralityOfSite Arg1:T712 Arg2:T711	
R186	SiteOf Arg1:T711 Arg2:T710	
R187	TestOrProcedureReveals Test:T709 Desc:T710	
T713	Pathology 19721 19756	ULTRASOUND-GUIDED LARGE CORE BIOPSY
A163	IntentVal T713 diagnosis
T714	Histology 19761 19786	INVASIVE DUCTAL CARCINOMA
A164	HistoryVal T714 new
A165	EpisodeDescription T714 FirstOccurrence
R188	TestOrProcedureReveals Test:T713 Desc:T714	
T715	Laterality 19699 19704	RIGHT
T716	Site 19691 19697;19715 19720	BREAST 05:00
T717	Site 19665 19671	BREAST
T718	Laterality 19659 19664	RIGHT
R189	LateralityOfSite Arg1:T718 Arg2:T717	
R191	SiteOf Arg1:T716 Arg2:T713	
T719	BiomarkerName 19806 19823	ESTROGEN RECEPTOR
T720	BiomarkerResult 19824 19847	Positive (1-3+, 80-90%)
A166	BiomarkerResultVal T720 Positive
R192	BiomarkerRel Arg1:T719 Arg2:T720	
T721	BiomarkerName 19861 19882	PROGESTERONE RECEPTOR
T722	BiomarkerResult 19884 19907	Positive (1-3+, 80-90%)
A167	BiomarkerResultVal T722 Positive
R193	BiomarkerRel Arg1:T721 Arg2:T722	
T723	BiomarkerName 19921 19925	HER2
T724	Pathology 19929 19932	IHC
T725	BiomarkerResult 19934 19942	Negative
A168	BiomarkerResultVal T725 Negative
R194	BiomarkerRel Arg1:T723 Arg2:T725	
T726	BiomarkerName 19952 19956	HER2
T727	Pathology 19957 19961	DISH
T728	Pathology 20015 20020	Ki-67
T729	RadPathResult 20021 20027	20-30%
R195	ResultOfTest Desc:T729 Test:T728	
T730	RadPathResult 20000 20009	ratio 1.1
R196	ResultOfTest Desc:T730 Test:T727	
R198	TestOrProcedureReveals Test:T713 Desc:T719	
R199	TestOrProcedureReveals Test:T713 Desc:T721	
R200	TestOrProcedureReveals Test:T713 Desc:T723	
T731	ClinicalCondition 20174 20187	breast cancer
T732	Site 20168 20173	right
R201	SiteOf Arg1:T732 Arg2:T731	
T733	BiomarkerName 20156 20158	ER
T734	BiomarkerResult 20158 20159	+
A169	BiomarkerResultVal T734 Positive
R202	BiomarkerRel Arg1:T733 Arg2:T734	
T735	BiomarkerName 20160 20163	HER
T736	BiomarkerResult 20164 20167	neg
A170	BiomarkerResultVal T736 Negative
R203	BiomarkerRel Arg1:T735 Arg2:T736	
T737	LymphNodeInvolvement 20202 20204	LN
T738	Site 20193 20201	axillary
R204	SiteOf Arg1:T738 Arg2:T737	
T739	ClinicalCondition 20225 20238	Breast cancer
A171	ContinuityVal T739 new
T740	ProcedureName 20270 20277	surgery
A172	IntentVal T740 treatment-curative
A173	TreatmentTypeVal T740 local
A174	NegationModalityVal T740 planned_in_future
T741	Datetime 20281 20289	11/05/17
R205	HappensAtOnDuring Arg1:T740 Arg2:T741	
T742	Radiology 20307 20314	imaging
T743	Pathology 20319 20328	pathology
T744	LymphNodeInvolvement 20392 20402	lymph node
T745	PatientCharacteristics 20378 20387	young age
T746	TreatmentType 20462 20474	chemotherapy
A176	NegationModalityVal T746 hypothetical_in_future
A177	TreatmentTypeVal T746 adjuvant
A178	TreatmentIntentVal T746 curative
R206	InclusionCriteriaFor Treatment:T744 Prob:T746	
R207	InclusionCriteriaFor Arg1:T745 Arg2:T746	
R208	InclusionCriteriaFor Arg1:T744 Arg2:T746	
T747	TreatmentType 20490 20506	hormonal therapy
T748	BiomarkerName 20539 20555	hormone receptor
T749	BiomarkerResult 20556 20564	positive
A175	BiomarkerResultVal T749 Positive
R209	BiomarkerRel Arg1:T748 Arg2:T749	
T750	ClinicalCondition 20529 20535	cancer
T751	ClinicalCondition 20585 20591	tumors
T752	LocalInvasion 20568 20584	locally advanced
T753	Size 20629 20633	size
A179	NegationModalityVal T753 uncertain_in_present
T754	LymphNodeInvolvement 20648 20659	lymph nodes
T755	MedicationRegimen 20731 20738	regimen
T756	MedicationName 20706 20719	anthracycline
R210	RegimenFor Arg1:T756 Arg2:T755	
A180	NegationModalityVal T755 uncertain_in_present
A181	NegationModalityVal T756 uncertain_in_present
R211	InclusionCriteriaFor Arg1:T748 Arg2:T755	
R212	InclusionCriteriaFor Arg1:T752 Arg2:T755	
T757	TreatmentType 20779 20791	chemotherapy
A182	TreatmentTypeVal T757 neoadjuvant
A183	TreatmentIntentVal T757 curative
T758	LymphNodeInvolvement 20810 20823	node positive
T759	ClinicalCondition 20844 20858	breast cancers
T760	LocalInvasion 20827 20843	locally advanced
R213	TumorDesc TumorDetails:T760 Desc:T759	
R214	InclusionCriteriaFor Arg1:T758 Arg2:T757	
R215	InclusionCriteriaFor Arg1:T760 Arg2:T757	
T761	ProcedureName 20895 20920	breast conserving surgery
A184	NegationModalityVal T761 hypothetical_in_future
A185	IntentVal T761 treatment-curative
A186	TreatmentTypeVal T761 local
A187	NegationModalityVal T757 hypothetical_in_future
T762	TreatmentType 20941 20950	treatment
A188	NegationModalityVal T762 hypothetical_in_future
A189	TreatmentTypeVal T762 neoadjuvant
A190	TreatmentIntentVal T762 curative
T763	Size 21000 21004	size
T764	LymphNodeInvolvement 21016 21033	nodal involvement
T765	GenomicTest 21049 21059	Mammaprint
A191	NegationModalityVal T765 hypothetical_in_future
A192	GenomicTestType T765 GeneExpression
T766	ClinicalCondition 21067 21072	tumor
T767	TreatmentType 21124 21136	chemotherapy
A193	NegationModalityVal T767 hypothetical_in_future
T768	ProcedureName 21155 21162	surgery
A194	NegationModalityVal T768 planned_in_future
T770	GenomicTest 21287 21297	Mammaprint
A195	GenomicTestType T770 GeneExpression
T771	GenomicTest 21476 21486	Mammaprint
A196	NegationModalityVal T771 hypothetical_in_future
A197	GenomicTestType T771 GeneExpression
A198	NegationModalityVal T770 hypothetical_in_future
T772	ClinicalTrial 21579 21586	Mindact
T773	ClinicalCondition 21656 21663	cancers
T774	TumorCharacteristics 21635 21655	clinical higher risk
R216	TumorDesc TumorDetails:T774 Desc:T773	
T777	GenomicTest 21769 21779	Mammaprint
A199	NegationModalityVal T777 hypothetical_in_future
A200	GenomicTestType T777 GeneExpression
T778	GenomicTestResult 21780 21788	Low Risk
R217	ResultOfTest Desc:T778 Test:T777	
T779	TreatmentType 21859 21871	chemotherapy
T780	TreatmentType 21877 21889	chemotherapy
A201	NegationModalityVal T780 hypothetical_in_future
A202	NegationModalityVal T779 negated
T781	TreatmentType 21972 21984	chemotherapy
A203	NegationModalityVal T781 hypothetical_in_future
T783	MedicationRegimen 22256 22258	TC
T784	Cycles 22263 22266	six
T785	MedicationRegimen 22291 22296	TaxAC
T786	MedicationRegimen 22414 22417	TC6
R218	TreatmentDesc Therapy:T784 Desc:T783	
T787	MedicationRegimen 22425 22430	TaxAC
T788	MedicationRegimen 22465 22468	TC6
T789	MedicationRegimen 22519 22522	TC6
T790	MedicationRegimen 22530 22535	TaxAC
T791	MedicationRegimen 22610 22612	TC
T792	MedicationRegimen 22641 22646	TaxAC
T793	MedicationRegimen 22678 22681	TC6
T794	MedicationRegimen 22700 22705	TaxAC
T795	BiomarkerName 22788 22790	ER
T796	BiomarkerResult 22790 22791	+
A204	BiomarkerResultVal T796 Positive
R219	BiomarkerRel Arg1:T795 Arg2:T796	
T797	LymphNodeInvolvement 22796 22800	node
A205	NegationModalityVal T797 negated
T798	MedicationRegimen 22881 22883	TC
T799	MedicationRegimen 22892 22897	TaxAC
T800	BiomarkerName 22910 22912	ER
T801	BiomarkerResult 22912 22913	+
A206	BiomarkerResultVal T801 Positive
R220	BiomarkerRel Arg1:T800 Arg2:T801	
T802	LymphNodeInvolvement 22928 22931	1-3
T803	GenomicTest 23017 23027	Mammaprint
A207	GenomicTestType T803 GeneExpression
A208	NegationModalityVal T803 hypothetical_in_future
T804	GenomicTestResult 23028 23037	High Risk
R221	ResultOfTest Desc:T804 Test:T803	
T805	TreatmentType 23048 23060	chemotherapy
T806	LymphNodeInvolvement 23069 23081	fewer than 3
T807	MedicationRegimen 23168 23175	regimen
T808	MedicationName 23143 23156	anthracycline
R222	RegimenFor Arg1:T808 Arg2:T807	
T810	MedicationName 23224 23232	Taxotere
A210	NegationModalityVal T810 hypothetical_in_future
T811	MedicationName 23237 23244	Cytoxan
T812	ClinicalCondition 23273 23282	infection
A211	NegationModalityVal T812 hypothetical_in_future
T813	Symptom 23284 23293	hair loss
A212	NegationModalityVal T813 hypothetical_in_future
T814	Symptom 23295 23302	fatigue
A213	NegationModalityVal T814 hypothetical_in_future
T815	ClinicalCondition 23323 23338	ovarian failure
A214	NegationModalityVal T815 hypothetical_in_future
R224	ConditionOrTreatmentCausesProblem Treatment:T810 Prob:T812	
A215	NegationModalityVal T811 hypothetical_in_future
R226	ConditionOrTreatmentCausesProblem Treatment:T810 Prob:T813	
R227	ConditionOrTreatmentCausesProblem Treatment:T810 Prob:T814	
R229	ConditionOrTreatmentCausesProblem Treatment:T811 Prob:T812	
R232	ConditionOrTreatmentCausesProblem Treatment:T811 Prob:T813	
R234	ConditionOrTreatmentCausesProblem Treatment:T811 Prob:T815	
T816	MedicationName 23357 23364	taxanes
A216	NegationModalityVal T816 hypothetical_in_future
T817	ClinicalCondition 23400 23410	neuropathy
A217	NegationModalityVal T817 hypothetical_in_future
R235	ConditionOrTreatmentCausesProblem Treatment:T816 Prob:T817	
T818	TreatmentType 23598 23610	chemotherapy
T819	TreatmentType 23545 23561	Penguin Cold Cap
T820	TreatmentType 23504 23517	scalp cooling
T821	TreatmentType 23532 23540	Dignicap
T823	MedicationRegimen 23678 23696	CDK 4/6 inhibitors
T824	ClinicalTrial 23709 23715	PALLAS
T825	ClinicalTrial 23720 23724	JPBE
T826	TreatmentType 23808 23824	hormonal therapy
T827	RadiationTherapyName 23870 23879	radiation
T828	TreatmentType 23913 23929	hormonal therapy
A219	NegationModalityVal T823 hypothetical_in_future
T830	ProcedureName 24035 24049	egg harvesting
T831	ProcedureName 24249 24260	egg harvest
T832	ProcedureName 24301 24308	surgery
A220	NegationModalityVal T832 planned_in_future
T833	ProcedureName 24323 24330	surgery
A221	NegationModalityVal T833 planned_in_future
A222	NegationModalityVal T802 hypothetical_in_future
T769	Age 23 25	36
R228	TestOrProcedureReveals Test:T465 Desc:T469	
A223	NegationModalityVal T504 hypothetical_in_future
T782	ProcedureOutcome 1440 1460	3 fertilized embryos
R230	ProcedureDesc Procedure:T503 Desc:T782	
R231	TestOrProcedureReveals Test:T481 Desc:T479	
R233	TestOrProcedureReveals Test:T482 Desc:T479	
T822	Datetime 832 840	10/02/17
R236	TestOrProcedureReveals Test:T485 Desc:T492	
R237	LateralityOfSite Arg1:T491 Arg2:T497	
T834	Datetime 2004 2009	today
R238	HappensAtOnDuring Arg1:T527 Arg2:T834	
R239	HappensAtOnDuring Arg1:T531 Arg2:T834	
A224	NegationModalityVal T537 hypothetical_in_future
A225	NegationModalityVal T538 hypothetical_in_future
T544	Employment 2607 2611	work
A65	NegationModalityVal T544 affirmed
A226	IsStoppedOrContinuing T544 continuing
A227	ExperiencerVal T544 patient
R241	LateralityOfSite Arg1:T565 Arg2:T563	
R88	LateralityOfSite Arg1:T565 Arg2:T564	
R91	LateralityOfSite Arg1:T588 Arg2:T594	
R111	ResultOfTest Desc:T590 Test:T584	
R240	HappensAtOnDuring Arg1:T602 Arg2:T601	
R124	SiteOf Arg1:T607 Arg2:T605	
R242	SiteOf Arg1:T607 Arg2:T606	
R243	LateralityOfSite Arg1:T615 Arg2:T617	
R244	TestOrProcedureReveals Test:T612 Desc:T618	
R245	TestOrProcedureReveals Test:T612 Desc:T622	
R246	TestOrProcedureReveals Test:T612 Desc:T619	
R247	TestOrProcedureReveals Test:T612 Desc:T623	
R248	TestOrProcedureReveals Test:T612 Desc:T626	
A228	NegationModalityVal T623 uncertain_in_present
A229	NegationModalityVal T631 planned_in_future
R249	SiteOf Arg1:T694 Arg2:T692	
A230	NegationModalityVal T695 uncertain_in_present
T545	Site 9921 9928	distant
R250	SiteOf Arg1:T545 Arg2:T695	
R190	LateralityOfSite Arg1:T715 Arg2:T716	
R251	TestOrProcedureReveals Test:T724 Desc:T723	
T547	BiomarkerResult 19983 19996	non-amplified
A231	BiomarkerResultVal T547 Negative
R197	BiomarkerRel Arg1:T726 Arg2:T547	
R252	TestOrProcedureReveals Test:T727 Desc:T726	
T835	Age 20075 20077	36
T836	PatientCharacteristics 20083 20089	female
A232	NegationModalityVal T763 uncertain_in_present
T837	MedicationModifier 21902 21916	little benefit
R253	ExclusionCriteriaFor Arg1:T837 Arg2:T780	
R254	ExclusionCriteriaFor Arg1:T777 Arg2:T779	
A233	NegationModalityVal T826 planned_in_future
A234	NegationModalityVal T827 planned_in_future
A235	NegationModalityVal T828 planned_in_future
A218	NegationModalityVal T830 affirmed
T829	ProcedureOutcome 24069 24093	three fertilized embryos
R255	ProcedureDesc Procedure:T830 Desc:T829	
A236	NegationModalityVal T831 hypothetical_in_future
A209	NegationModalityVal T820 hypothetical_in_future
A237	NegationModalityVal T821 hypothetical_in_future
A238	NegationModalityVal T819 hypothetical_in_future
A239	NegationModalityVal T818 hypothetical_in_future
R223	TreatmentAdministeredForProblem Treatment:T820 Prob:T813	
R225	TreatmentAdministeredForProblem Treatment:T821 Prob:T813	
R256	TreatmentAdministeredForProblem Treatment:T819 Prob:T813	
A240	NegationModalityVal T824 hypothetical_in_future
A241	NegationModalityVal T825 hypothetical_in_future
A242	NegationModalityVal T806 hypothetical_in_future
A243	NegationModalityVal T805 hypothetical_in_future
R257	InclusionCriteriaFor Arg1:T804 Arg2:T805	
A244	NegationModalityVal T808 hypothetical_in_future
A245	NegationModalityVal T807 hypothetical_in_future
R258	ExclusionCriteriaFor Arg1:T806 Arg2:T808	
A246	ExperiencerVal T772 others
A247	ExperiencerVal T783 others
A248	ExperiencerVal T785 others
T809	DiseaseState 22332 22369	invasive disease-free survival (IDFS)
A249	NegationModalityVal T809 hypothetical_in_future
A250	ExperiencerVal T809 others
T838	DiseaseState 22652 22663	4-year IDFS
A251	ExperiencerVal T838 others
A252	ExperiencerVal T793 others
A253	ExperiencerVal T794 others
A254	ExperiencerVal T791 others
A255	ExperiencerVal T792 others
A256	ExperiencerVal T790 others
A257	ExperiencerVal T789 others
A258	ExperiencerVal T788 others
A259	ExperiencerVal T787 others
A260	ExperiencerVal T786 others
T839	Cycles 22615 22616	6
A261	ExperiencerVal T839 others
R259	TreatmentDesc Therapy:T839 Desc:T791	
R260	SiteOf Arg1:T506 Arg2:T508	
R261	SiteOf Arg1:T506 Arg2:T509	
R262	SiteOf Arg1:T617 Arg2:T618	
R263	SiteOf Arg1:T620 Arg2:T623	
A262	NegationModalityVal T568 uncertain_in_present
A263	DiseaseStateVal T809 remission
A264	DiseaseStateVal T838 remission
R264	SizeOf Arg1:T460 Arg2:T461	
R265	SizeOf Arg1:T467 Arg2:T466	
R266	SizeOf Arg1:T488 Arg2:T489	
R267	SizeOf Arg1:T492 Arg2:T493	
R268	SizeOf Arg1:T515 Arg2:T512	
R269	SizeOf Arg1:T522 Arg2:T519	
R270	SizeOf Arg1:T524 Arg2:T523	
R271	SizeOf Arg1:T533 Arg2:T532	
R272	SizeOf Arg1:T553 Arg2:T552	
R273	SizeOf Arg1:T567 Arg2:T566	
R274	SizeOf Arg1:T589 Arg2:T586	
R275	SizeOf Arg1:T592 Arg2:T590	
R276	SizeOf Arg1:T606 Arg2:T605	
R277	SizeOf Arg1:T626 Arg2:T624	
R278	SizeOf Arg1:T636 Arg2:T633	
R279	SizeOf Arg1:T640 Arg2:T637	
R280	SizeOf Arg1:T648 Arg2:T645	
R281	SizeOf Arg1:T753 Arg2:T751	
R282	SizeOf Arg1:T763 Arg2:T766	
A265	ExperiencerVal T774 others
A266	ExperiencerVal T773 others
A267	NegationModalityVal T774 hypothetical_in_future
A268	NegationModalityVal T502 uncertain_in_present
T775	hpi_start 0 3	HPI
T776	hpi_end 4517 4521	2017
T840	ap_end 24330 24331	.
T841	ap_start 20036 20046	Assessment
T842	Symptom 6786 6797	sore throat
A132	NegationModalityVal T842 negated
T843	Symptom 6799 6815	nasal congestion
A133	NegationModalityVal T843 negated
T844	Symptom 6817 6831	vision changes
A269	NegationModalityVal T844 negated
T845	Symptom 6833 6838	cough
A270	NegationModalityVal T845 negated
T846	Symptom 6840 6850	chest pain
A271	NegationModalityVal T846 negated
T847	Symptom 6852 6859	dyspnea
A272	NegationModalityVal T847 negated
T848	Symptom 6861 6867	nausea
A273	NegationModalityVal T848 negated
T849	Symptom 6869 6877	vomiting
A274	NegationModalityVal T849 negated
T850	Symptom 6879 6893	abdominal pain
A275	NegationModalityVal T850 negated
T851	Symptom 6895 6904	headaches
A276	NegationModalityVal T851 negated
T852	Symptom 6906 6912	fevers
A277	NegationModalityVal T852 negated
T853	Symptom 6918 6953	change in bladder or bowel function
A278	NegationModalityVal T853 negated
